{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:54:28Z","timestamp":1761155668913},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1097\/cad.0b013e328360b9d6","type":"journal-article","created":{"date-parts":[[2013,3,29]],"date-time":"2013-03-29T12:28:11Z","timestamp":1364560091000},"page":"623-629","source":"Crossref","is-referenced-by-count":12,"title":["Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab"],"prefix":"10.1097","volume":"24","author":[{"given":"J\u00e9r\u00f4me","family":"Fayette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Bonnin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Ferlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Lallemant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Ramade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Favrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Zrounba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Poupart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"C\u00e9ruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210227","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009.","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"R3-9-20210227","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1056\/NEJM199301213280306","article-title":"Head and neck cancer.","volume":"328","author":"Vokes","year":"1993","journal-title":"N Engl J Med"},{"key":"R4-9-20210227","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.","volume":"349","author":"Forastiere","year":"2003","journal-title":"N Engl J Med"},{"key":"R5-9-20210227","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1200\/jco.2006.24.18_suppl.5517","article-title":"Long-term results of intergroup RTOG 91-11: a phase III trial to preserve the larynx - induction cisplatin5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy abstract.","volume":"24","author":"Forastiere","year":"2006","journal-title":"J Clin Oncol"},{"key":"R6-9-20210227","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"R7-9-20210227","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jnci\/djp007","article-title":"Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.","volume":"101","author":"Pointreau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R8-9-20210227","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"R10-9-20210227","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/annonc\/mdp573","article-title":"Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.","volume":"21","author":"Paccagnella","year":"2010","journal-title":"Ann Oncol"},{"key":"R11-9-20210227","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1200\/jco.2009.27.15_suppl.6009","article-title":"Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin5-FU or docetaxelcisplatin5-FU followed by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC) abstract.","volume":"27","author":"Hitt","year":"2009","journal-title":"J Clin Oncol"},{"key":"R12-9-20210227","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.","volume":"350","author":"Bernier","year":"2004","journal-title":"N Engl J Med"},{"key":"R13-9-20210227","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.","volume":"350","author":"Cooper","year":"2004","journal-title":"N Engl J Med"},{"key":"R14-9-20210227","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"R15-9-20210227","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"R17-9-20210227","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.radonc.2007.12.021","article-title":"Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement.","volume":"87","author":"Racadot","year":"2008","journal-title":"Radiother Oncol"},{"key":"R18-9-20210227","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1200\/jco.2009.27.15_suppl.6010","article-title":"Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study abstract.","volume":"27","author":"Lefebvre","year":"2009","journal-title":"J Clin Oncol"},{"key":"R19-9-20210227","first-page":"5501","article-title":"Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): results of the randomized phase II TREMPLIN study abstract.","volume":"29","author":"Lefebvre","year":"2011","journal-title":"Clin Oncol"},{"key":"R21-9-20210227","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/jco.2012.30.15_suppl.5501","article-title":"The PARADIGM trial: a phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC) abstract.","volume":"30","author":"Haddad","year":"2012","journal-title":"J Clin Oncol"},{"key":"R22-9-20210227","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1200\/jco.2012.30.15_suppl.5500","article-title":"DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN) abstract.","volume":"30","author":"Cohen","year":"2012","journal-title":"J Clin Oncol"},{"key":"R23-9-20210227","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"R24-9-20210227","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/1097-0142(19840901)54:5<811::AID-CNCR2820540508>3.0.CO;2-E","article-title":"Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck.","volume":"54","author":"Ensley","year":"1984","journal-title":"Cancer"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e328360b9d6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:18:17Z","timestamp":1620947897000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201307000-00009"}},"subtitle":["a study of 157 patients"],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e328360b9d6","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}